Get the Stockscreener App
20.92
0.19%
0.04
After Hours:
20.92
Innoviva Inc stock is traded at $20.92, with a volume of 895.59K.
It is up +0.19% in the last 24 hours and up +4.81% over the past month.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
See More
Previous Close:
$20.88
Open:
$20.95
24h Volume:
895.59K
Relative Volume:
0.98
Market Cap:
$1.32B
Revenue:
$330.50M
Net Income/Loss:
$145.42M
P/E Ratio:
12.68
EPS:
1.65
Net Cash Flow:
$157.96M
1W Performance:
+14.07%
1M Performance:
+4.81%
6M Performance:
+15.71%
1Y Performance:
+13.63%
1-Day Range:
$20.76
$21.13
1-Week Range:
$18.89
$21.13
52-Week Range:
$16.67
$22.00
Innoviva Inc Stock (INVA) Company Profile
Name
Innoviva Inc
Sector
Industry
Phone
(650) 238-9600
Address
1350 OLD BAYSHORE HIGHWAY, BURLINGAME
Compare INVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INVA
Innoviva Inc
|
20.92 | 1.32B | 330.50M | 145.42M | 157.96M | 1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Innoviva Inc Stock (INVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Initiated | Oppenheimer | Outperform |
| Jul-14-25 | Initiated | H.C. Wainwright | Buy |
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-20-22 | Initiated | Goldman | Neutral |
| Nov-20-17 | Initiated | Deutsche Bank | Hold |
View All
Innoviva Inc Stock (INVA) Latest News
Is Innoviva Inc. reversing from oversold territoryProduct Launch & Free Reliable Trade Execution Plans - Newser
What earnings revisions data tells us about Innoviva Inc.Earnings Summary Report & Safe Capital Growth Trade Ideas - Newser
Pattern recognition hints at Innoviva Inc. upsideQuarterly Market Summary & Reliable Price Action Trade Plans - Newser
Is Innoviva Inc. trading at a discountTrade Risk Summary & Long-Term Capital Growth Strategies - thegnnews.com
What risks could impact Innoviva Inc. stock performance2025 Key Highlights & Community Verified Swing Trade Signals - Newser
How Innoviva Inc. stock performs during market volatilityWeekly Trend Report & Verified Short-Term Trading Plans - Newser
What data driven models say about Innoviva Inc.’s futureJuly 2025 Reactions & Growth Focused Stock Reports - Newser
Earnings visualization tools for Innoviva Inc.July 2025 Rallies & Community Supported Trade Ideas - Newser
Innoviva, Inc. (NASDAQ:INVA) Shares Bought by US Bancorp DE - Defense World
Sentiment analysis tools applied to Innoviva Inc.Quarterly Trade Report & Technical Entry and Exit Tips - Newser
Can trapped investors hope for a rebound in Innoviva Inc.Quarterly Trade Report & Fast Moving Stock Watchlists - Newser
Tools to monitor Innoviva Inc. recovery probabilityJuly 2025 PreEarnings & Precise Swing Trade Entry Alerts - Newser
Will Innoviva Inc. continue its uptrendJuly 2025 Snapshot & Entry and Exit Point Strategies - Newser
Is it time to cut losses on Innoviva Inc.Market Movement Recap & Daily Profit Focused Stock Screening - Newser
Key External Factors That Drive Innoviva Inc. Stock Price MovementsTake Profit & Precise Swing Trade Entry Alerts - Newser
Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update - The Malaysian Reserve
Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award - itemonline.com
Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA - Business Wire
Is Innoviva Inc. a defensive stockWeekly Stock Report & Capital Efficient Trade Techniques - newsyoung.net
Is Innoviva Inc. being accumulated by smart moneyWealth Building Stock Watchlist - classian.co.kr
Sentiment Turns Positive on Innoviva Inc. — Reversal AheadRisk Adjusted Technical Entry Plan Gains Followers - sundaytimes.kr
Is Innoviva Inc. a play on infrastructure spendingFree Watchlist with Entry Points - newsyoung.net
Innoviva’s Royalties Keep Cash Flowing Despite Mixed Market Returns - Finimize
Why Innoviva (INVA) Is Up 5.7% After Reporting a Return to Profitability in Q2 - simplywall.st
Results: Innoviva, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - 富途牛牛
Innoviva’s Commercial Bet Pays Off As Shares Jump - Finimize
HC Wainwright Raises Innoviva Price Target to $45.00, Boosts Buy Rating - AInvest
Innoviva's Q2 Earnings Outperform Expectations; Price Target Raised to $45 by H.C. Wainwright - AInvest
Expert Outlook: Innoviva Through The Eyes Of 4 Analysts - 富途牛牛
Innoviva's Specialty Therapeutics, Royalty Portfolio to Drive Outperformance, Oppenheimer Says - MarketScreener
Analysts Initiate Coverage on Arm Holdings with Bullish Predictions - AInvest
This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday - Benzinga
Innoviva, Inc. Just Recorded A 54% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st
Innoviva, Inc. Just Beat EPS By 54%: Here's What Analysts Think Will Happen Next - ca.finance.yahoo.com
Zurcher Kantonalbank Zurich Cantonalbank Cuts Holdings in Innoviva, Inc. (NASDAQ:INVA) - Defense World
Innoviva Inc Q2 2025 Earnings: Revenue Misses Estimates, EPS at $1.01, Royalty Revenue at $67.3 Million - AInvest
Innoviva Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Avantax Advisory Services Inc. Has $372,000 Stock Holdings in Innoviva, Inc. (NASDAQ:INVA) - Defense World
Innoviva Reports Strong Q2 2025 Financial Results - The Globe and Mail
Innoviva: Q2 Earnings Snapshot - New Haven Register
Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress - BioSpace
Innoviva (INVA) Q2 Sales Jump 64% - AOL.com
Innoviva (INVA) Q2 Sales Jump 64% - The Motley Fool
Innoviva Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Innoviva Q2 revenue $67.3mln, IST sales up 54% YoY to $29mln. - AInvest
Earnings Flash (INVA) Innoviva, Inc. Reports Q2 Revenue $100.3M, vs. FactSet Est of $92.0M - MarketScreener
Innoviva Inc. Inches Toward Key Resistance — Will It BreakStock Selection With High Accuracy Based on Models - metal.it
What catalysts could drive Innoviva Inc. stock higher in 2025Invest confidently with real-time data - Jammu Links News
Innoviva Inc Stock (INVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):